Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ZOM stock has had an incredible few months, but it's time to jump off while you still have time. The post Take Profits in Zomedica While They're Still There for the Taking appeared first on InvestorPlace.

Take Profits in Zomedica While They're Still There for the Taking

Zomedica just raised approximately $200 million from a bought deal. Loaded with cash, ZOM stock look ready to move higher.

Despite Market Over-Enthusiasm, Zomedica Is Worth Real Consideration

ZOM stock appears to be a trader's best friend right now, but is this stock truly a viable long-term investment opportunity? The post Zomedica Stock Has Soared 880% This Year — Here's Why appeared first on InvestorPlace.

Zomedica Stock Has Soared 880% This Year — Here's Why

Ocugen, Inc.

Better Buy: Ocugen vs. Zomedica

Zomedica raised $173.5 million in a stock offering and saw ZOM stock take a hit as a result. But the stock price has almost fully rebounded.

Zomedica Still Looks Promising After Public Offering Hiccup

SNDL Inc.

Two popular stocks have made some investors rich over the past month.

Better Buy: Sundial Growers vs. Zomedica

ANN ARBOR, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the underwriter of its previously announced public offering of has exercised in full its over-allotment option to purchase an additional 13,697,368 common shares of Zomedica at a price to the public of $1.90 per share, less underwriting discounts and commissions. After giving effect to the full exercise of the over-allotment option, the gross proceeds are approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zomedica.

Zomedica Corp. Announces Full Exercise of Over-Allotment Option by Underwriter

With the market reading the popularity of ZOM stock as a negative, dip buyers can seize the window of opportunity while it exists. The post Uptrend Should Resume Soon for Zomedica Stock appeared first on InvestorPlace.

Uptrend Should Resume Soon for Zomedica Stock

Churchill Capital Corp IV

Express

Jaguar Health

Koss

Cenntro Electric Group

Nokia

Palantir Technologies

It may be fun to dabble in meme stocks. But, don't consider it a surefire path to investing profits.

9 Meme Stocks That Social Media Won't Shut Up About

Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.

What's in Store for Zomedica (ZOM)This Earnings Season?

While the pet care industry is a compelling one, ZOM stock occupies one of its riskiest subsegments, making the narrative insanely treacherous. The post Do You Love Your Pets That Much for Zomedica Stock to Be Worth Billions?

Do You Love Your Pets That Much for Zomedica Stock to Be Worth Billions?

ANN ARBOR, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the closing of its previously announced public offering of 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. As previously announced, Zomedica also has granted to the underwriter a 30-day option to purchase up to 13,697,368 additional common shares at the public offering price, less underwriting discounts and commissions.

Zomedica Corp. Announces Closing of $173.5 Million Bought Deal

Bally's

Dillard's

Ideanomics Inc

Investors highlighting overvalued stocks often look to the biggest names, but these four smaller names have valuation concerns of their own. The post 4 Overvalued Small-Cap Stocks to Sell appeared first on InvestorPlace.

4 Overvalued Small-Cap Stocks to Sell

Bottom line: there's only call for ZOM stock: be careful, even if shares pull back from here. The post Zomedica Stock Could Rise Even Higher, But It's Still a Gamble appeared first on InvestorPlace.

Zomedica Stock Could Rise Even Higher, But It's Still a Gamble

ZOM stock has a lot of potential for posting major gains in the near term, but pet care play Zomedica needs to make an good first impression. The post Use the Wait-and-See Approach With Zomedica Stock appeared first on InvestorPlace.

Use the Wait-and-See Approach With Zomedica Stock

Castor Maritime Inc

Globalstar

Trading is booming in these popular penny stocks.

Why Globalstar, Castor Maritime, and Zomedica Stocks Surged Today

Zomedica has potential, certainly. A nearly 3,000% rally in ZOM stock and a $1.5 billion market capitalization price in that potential — and then some.

Zomedica Stock Has Gotten Out of Hand

The stock price of Zomedica Corp. (NYSE American: ZOM) is trading at over 7% pre-market as of 8:30 AM ET. This is why it happened.

ZOM Stock Price Increases Over 7% Pre-Market: Why It Happened

Zomedica's massive rally could be cooling off. A discounted secondary offering may have halted ZOM stock's double-digit gains in their tracks.

ZOM Stock: Why Red-Hot Zomedica Shares Are on the Move Today

Shares of Zomedica Corp. tumbled 17.0% in premarket trading Tuesday, after the veterinary health company's common stock offering, that was upsized by nearly seven-fold, priced at a deep discount. Trading volume of 40.1 million shares made Zomedica's stock the most actively traded ahead of the open.

Zomedica stock tumbles on heavy volume after public stock offering upsized 7-fold 'due to demand'

Zomedica Corp (NYSE: ZOM) has sharply increased the size of the previously announced public offering to 91.3 million at $1.90 per share, raising gross proceeds of $173.5 million, compared to an earlier offering of mere 13 million shares for $25 million.  The offer price is about 30% below its last closing price of $2.70 on Monday.

Zomedica Raises $173.5M At 30% Discount, Shares Plunge

ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a  veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to satisfaction of customary closing conditions.

Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million

The veterinary health specialist is cashing in on its recent gains.

Why Zomedica Stock Soared Today and Then Plunged in After-Hours Trading

ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a  veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 13,157,895 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to satisfaction of customary closing conditions.

Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) is trading at over 45% as of 2:16 PM ET today. This is why it happened.

News for Zomedica Stock (ZOM)